The Story: A Brand That Refused to Trade Its Future for Its Present
Nineteen months. That is all it took for IM8 (the AI-native wellness brand co-founded by serial entrepreneur Danny Yeung and global icon David Beckham) to become, by its own account, the fastest-growing premium supplement brand ever recorded. nasdaq.com
By June 2026, IM8 had delivered over 50 million total servings, was shipping approximately 200,000 servings per day, and generated roughly $17 million in revenue in a single month, its strongest on record. The brand was operating across 43 countries, riding an AI-driven direct-to-consumer engine that had quietly built one of the most efficient subscriber acquisition machines in consumer health.
Behind the momentum, though, was a capital structure decision that would define the company’s next chapter. IM8 needed to scale its marketing aggressively: across digital performance channels, connected TV, ambassador partnerships, content, and new markets. The capital requirement was not small. It was nine-figure territory. And the path chosen would determine not just how fast the brand grew, but who would own that growth when it compounded.
Yeung had already proven he knew how to build and sell businesses. He launched daily-deals platform uBuyiBuy in 2010, and Groupon acquired it within six months. He then ran Groupon East Asia, scaling it to over $130 million in annual revenue. citybiz.co He did not need to be taught what dilution costs a founder at scale. This time, he was looking for a different kind of deal.
The Decision: Breaking the Binary
The conventional playbook for a high-growth consumer brand in this position is familiar and brutal: raise a dilutive equity round, surrender 20–30% of the company to institutional investors, accept new board seats and governance constraints, and hope the valuation at the next round is high enough to justify the dilution. angelinvestorsnetwork.com Alternatively, a founder throttles growth to stay cash-flow self-funding, effectively capping the ceiling to protect the floor.
Prenetics, IM8’s parent and a NASDAQ-listed company (ticker: PRE), entered this decision from a position of genuine financial strength. The company held approximately $139.7 million in combined cash, current financial assets, and escrowed consideration as of May 31, 2026, and had already announced a $40 million share repurchase program, signaling confidence in the equity, not desperation for capital. stocktitan.net
On July 14, 2026, Prenetics announced a third way. IM8 closed a $1 billion growth financing arrangement with General Catalyst’s Customer Value Fund (CVF), a non-dilutive facility structured to finance up to 70% of IM8’s global marketing spend. theglobeandmail.com
The structure was purpose-built around IM8’s economics. Each month, General Catalyst would fund up to 70% of that month’s marketing spend. Those customers would form a discrete cohort, tracked in isolation. General Catalyst would receive a capped share of cohort-level income until a fixed multiple of deployed capital was repaid, after which all value from those customers reverts permanently to IM8.
Critically: the arrangement does not involve the issuance of any equity, warrants, or convertible instruments to General Catalyst, and is tracked separately for each monthly cohort of customers. No board seat. No cap table entry. No fixed maturity. No financial covenants. The repayment obligation is bounded entirely by the revenue the funded customers generate, not by the consolidated Prenetics balance sheet. investingnews.com
The blended payback premium ranges from approximately 3.5% for cohorts repaid within three months to roughly 7.6% for cohorts repaying over six to twelve months, a hard cap of 1.17× on any deployed tranche. Compare that to the permanent, compounding cost of a 25%+ equity dilution at a growing company’s inflection point.
The Outcome: What the Numbers Say
The economic case for this structure rests on one number that Yeung has made central to his public narrative: “Every dollar we have ever spent acquiring customers has already returned $1.44 in gross profit, and that number rises every month, because these are subscribers.” Every mature IM8 cohort has exceeded the performance thresholds General Catalyst diligenced against.
When a customer acquisition dollar returns $1.44 in gross profit on a subscriber basis, meaning the revenue compounds month after month as the cohort matures, the correct question is never whether the spend is too high. It is whether the capital to fund it is being sourced efficiently.
The growth trajectory tells the rest of the story. Prenetics raised its full-year 2026 IM8 revenue guidance to $210–220 million, up from $190–210 million previously, its second upward revision of the year, and projects IM8 to reach $300 million in annualized run-rate revenue by year-end 2026 and over $400 million in full-year 2027.
Now consider the counterfactual. Had Prenetics raised a dilutive equity round to fund the same marketing scale (say, a $200 million raise at a generous valuation) existing shareholders might have surrendered 15–25% of the company permanently. On a path to $400+ million in revenue with potential multi-billion dollar enterprise value ambitions, that dilution would compound into hundreds of millions of dollars of lost founder and shareholder value. The CVF structure converts what would have been permanent ownership surrender into a capped, time-limited cost of capital with a maximum return multiple of 1.17× per cohort.
Revenue-based financing as a category is now growing at over 62% annually and reached $9.77 billion in market volume in 2025, and deals like IM8’s represent the frontier of that evolution: institutional scale, sophisticated structure, and genuine zero-dilution mechanics. spectup.com
The Lessons: A Framework for Founders Facing the Same Choice
The IM8/General Catalyst deal is not a template that fits every company. But it crystallizes a set of principles that any founder, operator, or capital allocator should carry into their next financing decision.
1. The binary was always false.
Historically, high-growth consumer businesses have faced a binary choice when scaling customer acquisition: raise dilutive equity capital, or hold back on growth to preserve cash reserves. The CVF structure demonstrates a third architecture is now available at institutional scale, and it is cohort-matched, self-liquidating, and bounded in its return. quiverquant.com
2. Non-dilutive capital works when the unit economics are provable.
General Catalyst did not write a billion-dollar check on narrative. They examined every monthly cohort at the transaction level. The deal closed because IM8’s cohort economics were not just strong; they were demonstrably consistent. Non-dilutive funding has become a core part of capital strategy for venture-backed and privately held companies, but it remains disciplined: the structure demands proof, not projection. axisgroupventures.com
3. The cost of dilution is permanent; the cost of structured debt is finite.
A 1.17× hard cap on a funded cohort is a finite, bounded cost. A 20% equity grant to a Series B investor is a permanent, compounding cost that grows with enterprise value. By Series C, founding teams often own less than 10% of the company they built, not because the business underperformed, but because each capital raise extracted permanent ownership in exchange for temporary capital. angelinvestorsnetwork.com
4. Position of strength matters.
Prenetics entered this arrangement with $139.7 million in liquidity and no debt. The CVF structure was chosen for strategic reasons, not survival. Founders who reach for non-dilutive structures from a position of desperation often accept worse terms. The best non-dilutive deals are done when you do not need them.
5. Match the instrument to the cash flow pattern.
CVF works for IM8 because IM8’s customers are subscribers: recurring, predictable, and measurable at the cohort level. The repayment is self-liquidating from the revenue those customers generate. Non-dilutive structures are especially advantageous for businesses with recurring revenue models or predictable income streams. novelcapital.com For a one-time product sale with no retention, this architecture breaks down.
Key Insights
- Cohort-matched capital is the new frontier of non-dilutive financing. Structures that tie repayment directly to the revenue generated by funded customer cohorts eliminate balance-sheet recourse risk and align investor and operator incentives around the same economic unit.
- A capped 1.17× return multiple is not the same as giving away 20% of your company. Founders who conflate the cost of structured non-dilutive capital with the cost of equity are systematically undervaluing their future ownership.
- Proven unit economics unlock institutional non-dilutive capital at scale. General Catalyst’s $1 billion commitment was underwritten at the cohort level, not the company level. The diligence demanded proof of each month’s returns, not a pitch deck.
- Non-dilutive financing from a position of strength produces structurally better terms. The best time to raise non-dilutive capital is when you do not urgently need it, Prenetics entered this deal with $139.7 million in liquidity and zero debt, giving it negotiating leverage most founders never enjoy.
- The market is pricing this shift. Revenue-based financing grew to $9.77 billion in volume in 2025, up 62%+ annually. The IM8/General Catalyst deal signals that this category is now operating at nine-figure institutional scale, and the playbook is being rewritten for founders who refuse to accept the equity trap as inevitable.
